Vertex on track for “five launches in five disease areas over a five-year period” through emerging pain and renal franchises.

The cost of medication was too high for thousands of CF sufferers around the world. Now a Bangladeshi company is making a generic version that will change lives ...

Cystic fibrosis causes a buildup of mucus in the lungs that can lead to infection, and often death in children and young ...

Now, my prediction is three in particular are poised to outperform over the next few years: These stocks could be the ...

In January, the Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Journavx, a non-opioid oral pain signal inhibitor for acute pain. This marked the first approval ...

Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in ...

(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% ...

Optum Rx, a pharmacy benefit manager owned by one of the country’s largest insurance companies, UnitedHealth Group, has added a new, much-anticipated pain drug to some of its commercial formularies.

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...

Enlaza Therapeutics ("Enlaza" or the "Company"), the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals ("Vertex") ...

Third, this stock provides stability to investors' portfolios in the event the economy takes a turn for the worse in the new year. Enbridge ranks as the largest natural gas utility in North America ...